(281)-719-8904 KenFaulkenberry@AAAMP.com

Gilead Sciences (GILD) Dividend Stock Analysis

by | Dividend Stock Analysis

Biotechnology Research Graphic
Gilead Sciences Logo
Cell Membrane

Gilead Sciences Dividend

(updated 2/23/18)

Gilead Sciences initiated a dividend in 2015 and increased the dividend in 2016 and 2017.

Price: $80.92
Dividend Yield: 2.8%

Current Dividend: $2.28
Cash Flow From Operations (CFO) Per Share (ttm): $9.32
Free Cash Flow Per Share (ttm): $8.91

Market Capitalization: 106 B
Enterprise Value: 104 B

Dividend Analyzer Checklist

(updated February 2018)

Valuation Score (32/34 points)

Free Cash Flow Yield (ttm): 10.9% (17/17 points)
EV to EBIT (ttm): 6.7
EV to EBITDA (ttm): 6.1 (15/17 points)
Price to Sales Ratio (ttm): 4.0
Price to Book Value (ttm): 4.4
Price to Earnings Ratio (P/E) (ttm): 9
PE 10: 20

Profitability Score (28/33 points)

Operating Earnings Yield (ttm): 14.8 (15/15 points)
Net Income (ttm): $11601 M
Gross Profit (ttm): $23288 M
Total Assets: $64662
Gross Profitability Ratio = Gross Profit / Total Assets: 36% (13/18 points)
Cash Return On Invested Capital (CROIC)(tttm): 24%
Return on Invested Capital (ROIC): 24%

Dividend Safety Score (26/33 points)

Dividend Payout Ratio (ttm): 23%
Cash Dividend Payout Ratio (ttm): 23% (12/12 points)
Net Financial Debt: $875 M
Total Assets: $64662 M
Net Financial Debt / Total Assets: 1% (10/12 points)
Net Financial Debt to EBITDA (ttm): 154%
Piotroski Score (1-9) (TTM): (4/9 points)

TOTAL POINTS – (86/100) (50 is an average score)

Latest Earnings Report: 2/06/18
Next Earnings Report: n/a

 

Stay Updated All the Time!

DVB Analyzer Bundle: Dividend Analyzer Newsletter & Dividend Sortable Excel Spreadsheet

DVB Portfolio Bundle: Dividend Portfolio & Treasure Trove Twelve Newsletters

SPECIAL 4 For 1 Price: DVB Full Membership

Learn More

Rankings & Recommendations

(updated February 2018)

Gilead Sciences (GILD) is ranked #6 (out of 432) overall and #1 (out of 36) in the Healthcare sector by the Dividend Analyzer.

 

Type of Investor / Recommendation
Large Diversified Dividend Portfolios / A Top Choice
Looking For Exposure to the Healthcare Sector / A Top Choice
Deep Value Investors / A Top Choice

Position Disclosures:
DVB Portfolio Stocks – Long
AAAMP Global Value Portfolio – Long
AAAMP Retirement Growth & Income Portfolio – Long
AAAMP Treasure Trove Twelve Portfolio – Long

Company Description

Sector: Healthcare
Industry: Biotechnology

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and markets innovative medicines to treat life- threatening infectious diseases, with the largest part of its portfolio focused on HIV and hepatitis B and C.

Gilead Sciences if known for making strategic acquisitions. Investments in Corus Phama, Myogen, CV Therapeutics, Arresto Biociences an Calistoga have expanded their base to include pulmonary and cardiovascular diseases and cancer.

The acquisition of Pharmasset secured the right to hepatitis C drug Sovaldi (part of combination drug Harvoni), and the Kite purchase advanced Gilead’s involvement in cell therapy in oncology.

Discover, Compare, and Evaluate Dividend Stocks Without Emotional Bias

DVB Analyzer Bundle: Dividend Analyzer Newsletter & Dividend Sortable Excel Spreadsheet - $68/year

DVB Portfolio Bundle: Dividend Portfolio & Treasure Trove Twelve Newsletters - $68/year

SPECIAL 4 For 1 Price: DVB Full Membership: Both Bundles for $99/year

Learn More
Disclaimer: While Arbor Investment Planner has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability, or completeness of third-party information presented herein. The sole purpose of this analysis is information. Nothing presented herein is, or is intended to constitute investment advice. Consult your financial advisor before making investment decisions.
Share This